Table 1 Baseline demographic characteristics of the CKD stages 4 patients.

From: Machine learning models for predicting short-term progression in patients with stage 4 chronic kidney disease: a multi-center validation study

Characteristics

Participants

Development cohort (n = 346)

Validation cohort (n = 105)

Age, years

53.83 ± 13.48

53.59 ± 15.67

Gender, no.

  

 Male

167 (48.30)

63 (60.0)

 Female

179 (51.70)

42 (40.0)

Short-term progressiona

  

 Yes (< 25 weeks)

170 (49.10)

56 (53.30)

 No ( > = 25 weeks)

176 (50.90)

49 (46.70)

 Scr

483.90 ± 330.3

443.69 ± 122.54

 Serum potassium

3.53 ± 1.58

4.72 ± 0.87

 Serum sodium

131.29 ± 12.04

139.77 ± 4.30

 Alb (g/L)

26.70 ± 12.48

26.43 ± 12.97

 CysC

3.55 ± 1.20

6.52 ± 3.21

 BUN

18.91 ± 7.43

20.82 ± 8.13

 HDL-C

1.03 ± 0.30

1.17 ± 0.60

 Serum glucose

6.20 ± 3.32

7.60 ± 3.0

 UA

347.43 ± 195.2

371.43 ± 184.38

Urea/Crea, No.

  

 Median (IQR)

41.24

0.05

 Alb/Glo

0.92 ± 0.46

1.12 ± 0.33

  1. Scr serum creatinine, Alb serum Albumin, CysC serum Cystatin C, BUN blood urea nitrogen, HDL-C high-density lipoprotein cholesterol, UA uric acid, Alb/Glo serum albumin and globulin ratio. aShort-term progression is defined as CKD 4 progression into CKD 5 within 25 weeks (approximately six months).
Back to article page